96850-13-4

Usage

Uses

Used in Neuroscientific Research:
Indatraline Hydrochloride is used as a competitive inhibitor of 3H-dopamine ([3H]DA) to study its effects on the trans-activator of transcription (Tat) protein and cocaine-induced inhibition of uptake of [3H]DA.
Used in Pharmaceutical Research:
Indatraline Hydrochloride is used as a dopamine transport blocker to study its effects on trace amine-associated receptor 1 (TAAR1)-transfected mice cells, which can help in understanding the role of TAAR1 in various physiological processes.
Used in Oncology Research:
Indatraline Hydrochloride is used as a nonselective monoamine transport inhibitor to study its anti-angiogenic activities in glioblastoma multiforme (GBM), a highly aggressive brain tumor. This research can potentially lead to the development of new therapeutic strategies for treating GBM and other cancers.

Biochem/physiol Actions

Indatraline is a non-selective monoamine transport inhibitor. It inhibits the reuptake of neurotransmitters, such as serotonin, norepinephrine and dopamine. It exhibits anti-depressant and anti-angiogenic effects. Indatraline also plays a role in inducing autophagy.

Upstream product

• 79560-19-3 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 439134-46-0 1-(3,4-dichlorophenyl)-1,2-dihydronaphthalene 
• 866018-46-4 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphthalen-1-ol 
• 7312-27-8 3,4-Dichlorocinnamic acid 
• 71-43-2 benzene 
• 80272-06-6 3-(3',4'-dichlorophenyl)-3-phenylpropanoic acid 
• 80272-59-9 cis-3-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-ol 
• 74-89-5 methylamine 
• 100-52-7 benzaldehyde 
• 85662-98-2 3-(3',4'-dichlorophenyl)-indan-1-one 
• 2025-40-3 ethyl benzylidenecyanoacetate 
• 203317-12-8 2-Cyano-3-(3,4-dichloro-phenyl)-3-phenyl-propionic acid ethyl ester 
• 113093-58-6 C₁₇H₁₆Cl₂O₂ 
• 748724-48-3 LNK 131 

Relevant academic research and scientific papers

Discovery of Novel Sertraline Derivatives as Potent Anti- Cryptococcus Agents

Treatment of life-threatening cryptococcal meningitis (CM) is highly challenging due to the limited efficacy of the available antifungal drugs. Antidepressant sertraline (SER) has been proposed to be a potential antifungal agent for CM. However, clinical studies indicated that SER failed to achieve the expected therapeutic effects. Herein, novel SER derivatives were designed by scaffold hopping, and they showed improved anticryptococcal activity both in vitro and in vivo. In particular, compound D16 was identified as a promising anti-CM agent with a new antifungal mode of action. It acted by blocking the biosynthesis of ergosterol through the inhibition of Δ5,6-desaturase. This study provides a new target and a drug-like candidate for CM treatment.

Sertraline derivative and preparation method and application thereof

The invention discloses a sertraline derivative or a medicinal salt thereof. The structural general formula of the sertraline derivative is shown in the specification. The sertraline derivative has a good inhibition effect on cryptococcus neoformans, particularly, the compound D16 disclosed by the invention has a relatively good inhibition effect on candida glabrata 9073, candida tropicalis 10186, cryptococcus neoformans, candida albicans 5314, candida albicans 904, candida tropicalis 10186, drug-resistant candida albicans 103 and cryptococcus gottii.

Asymmetric total synthesis of (+)-indatraline via diastereoselective amination of chiral ethers using chlorosulfonyl isocyanate

A concise asymmetric total synthesis of (+)-indatraline from readily available cinnamic acid is described. The key steps include Corey's oxazaborolidine-catalyzed asymmetric carbonyl reduction and a highly stereoselective amination of chiral benzylic ether with retention of stereochemistry using chlorosulfonyl isocyanate.

Enantiopurity determination of the enantiomers of the triple reuptake inhibitor indatraline

The present study describes the development of two approaches for the determination of the enantiopurity of both enantiomers of indatraline. Initially, a method was developed using different chiral solvating agents (CSAs) for diastereomeric discrimination regarding signal separation in 1H nuclear magnetic resonance (NMR) spectroscopy, revealing MTPA as a promising choice for the differentiation of the indatraline enantiomers. This CSA was also tested for its ideal molar ratio, temperature, and solvent. Optimized conditions could be achieved that made determination of enantiopurity for (1R,3S)-indatraline up to 98.9% enantiomeric excess (ee) possible. To quantify even higher enantiopurities, a high-performance liquid chromatography (HPLC) method based on a modified β-cyclodextrine phase was established. The influence of buffer type, concentration, pH value, percentage and kind of organic modifier, temperature, injection volume as well as sample solvent on chromatographic parameters was investigated. Afterwards, the reliability of the established HPLC method was demonstrated by validation according to the ICH guideline Q2(R1) regarding specificity, accuracy, precision, linearity, and quantitation limit. The developed method proved to be strictly linear within a concentration range of 1.25-1000 μM for the (1R,3S)-enantiomer and 1.25-750 μM for its mirror image that enables a reliable determination of enantiopurities up to 99.75% ee for the (1R,3S)-enantiomer and up to 99.67% ee for the (1S,3R)-enantiomer.

TREATMENT OF NEURODEGENERATIVE DISEASES USING INDATRALINE ANALOGS

Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson''s disease, diffuse Lewy body disease, and multiple system atrophy, or other neurodegenerative diseases (e.g., amyotrophic lateral sclerosis, Huntington''s disease, and Alzheimer''s disease) are provided. The treatment including administering to a subject an indatraline derivative that inhibits the aggregation of a-synuclein.

Iodine(III)-promoted ring contraction of 1,2-dihydronaphthalenes: A diastereoselective total synthesis of (±)-indatraline

Equation presented A new approach for the synthesis of (±)- indatraline, which is a 3-phenyl-1-indanamine that displays several biological activities, is described. The strategy features as the key step a diastereoselective ring contraction of a 1,2-dihydronaphthalene promoted by Phl(OTs)OH, to construct the indan ring system. The oxidative rearrangement of other 1,2-dihydronaphthalenes was also investigated, generalizing this method to obtain indans.